Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.
Location: United States, California, San Diego
Employees: 51-200
Total raised: $706M
Founded date: 2017
Investors 5
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | Omega Fund... | omegafunds... |
| - | EcoR1 Capi... | ecor1cap.c... |
| - | Altitude L... | altitudels... |
| - | Bay City C... | baycitycap... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 07.02.2019 | IPO | $276M | - |
| 24.07.2018 | Series B | $230M | - |
| 05.01.2018 | Seed | $100M | - |
| 05.01.2018 | Series A | $100M | - |
Mentions in press and media 15
| Date | Title | Description |
| 25.02.2021 | Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update | SAN DIEGO--(BUSINESS WIRE)--Feb 25, 2021-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, infl... |
| 08.02.2019 | Gossamer Bio becomes 2019’s second biotech ‘unicorn’ to go public | Gossamer is the second “unicorn” – a company with a value of at least $1 billion – to go public this year. The first was Alector, which also announced Thursday that it would go public. According to Renaissance Capital, Gossamer’s value woul... |
| 07.02.2019 | Gossamer Bio pulls off $276M IPO to push a trio of programs through the clinic | - |
| 24.07.2018 | Gossamer Bio secures $230 million in Series B funding round | The company was founded by former Receptos executives Faheem Hasnain and Sheila Gujrathi. Hasnain, who had been CEO, has been appointed as executive chairman, while Gujrathi is replacing him as CEO. The San Diego-based company plans to focu... |
| 24.07.2018 | Hillhouse Capital leads $230m Series B in US-based Gossamer Bio | Premium Beijing and Hong Kong-based Hillhouse Capital has led a $230-million Series B in Gossamer Bio Inc, a San Diego-based biotechnology company that develops therapeutic products, according to a statement. Continue reading this story wit... |
| 23.07.2018 | Gossamer Bio Gains $230M | San Diego-based Gossamer Bio, a biotechnology company focused on therapeutics in the autoimmune, allergy/inflammation, and immuno-oncology disease areas, said on Monday that it has raised $230M in a Series B funding round. The massive fundi... |
| 23.07.2018 | Gossamer Bio nets $230M in series B to advance portfolio against undisclosed targets W h i t e p a p e r Weighing the Costs: | Gossamer Bio netted $230 million in a series B financing round—on the heels of its $100 million launch in January—to accelerate the company’s growth and fund clinical trials of candidates with undisclosed targets in immunology, inflammation... |
| 23.07.2018 | Gossamer Bio nets $230M in series B to advance portfolio against undisclosed targets | Gossamer Bio netted $230 million in a series B financing round—on the heels of its $100 million launch in January—to accelerate the company’s growth and fund clinical trials of candidates with undisclosed targets in immunology, inflammation... |
| 06.01.2018 | Gossamer Bio Raises $100M in Series A Funding | Gossamer Bio, Inc., a San Diego, CA-based new biopharmaceutical company focused on the discovery and development of novel and differentiated therapeutic products to address high unmet needs of targeted patient populations, raised $100m in S... |
| 05.01.2018 | Gossamer Bio Launches with $100M Seed Round | SAN DIEGO, CA, Gossamer Bio is launching with $100M seed round of capital provided by Omega Funds and a Series A Preferred Stock round co-led by ARCH Venture Partners and Omega Funds. >> Click here for more funding data on Gossamer... |
Show more